Skip to navigation Skip to content



Clemastine: Follow-Up Imaging Study Shows Some Evidence of Myelin Repair

June 29, 2023

A small, phase II clinical trial of the oral antihistamine clemastine previously showed that it modestly improved the transmission of electrical signals in the optic nerve in participants with MS who had optic nerve damage. Now, this team has published new data, based on follow-up studies of this population using novel imaging techniques to examine a major nerve center in the brain called the corpus callosum. This follow-up study, while not a primary outcome of the original study, shows evidence of myelin repair in this nerve center, which was maintained even after treatment stopped.

More studies are needed before the full benefits and risks of this approach can be verified. Several studies are underway. This and other strategies may help to restore lost function in MS, one of the Pathways to Cures identified in the National MS Society roadmap. Learn more about this global effort to find cures for all people with MS.
Read more about this study from UCSF
Read the paper in Proceedings of the National Academy of Science

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system. Symptoms range from numbness and tingling to blindness and paralysis, and there is currently no cure for MS. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. An estimated 1 million people live with MS in the United States. Most people with MS are diagnosed between the ages of 20 and 50, and it affects women three times more than men.


© 2023 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization. Its Identification Number (EIN) is 13-5661935.